logo
How Australia is failing dying children

How Australia is failing dying children

News.com.au7 hours ago
EXCLUSIVE
Warning: This story discusses the death of a child and paediatric palliative care
Looking back now, 51-year-old Alix can see the signs that her irreverent, curious youngest child, Sofia, was seriously ill much earlier than anyone realised.
In early 2018, the six-year-old was getting headaches. Somewhat inexplicably – given Sofia's happy and relaxed family and school life – the doctors put the issue down to 'stress'.
Only when Alix, her husband and their eldest daughter holidayed with Sofia in Bali later that year did things become impossible to ignore.
To Alix, Sofia seemed unusually thin, and her stomach was swollen.
On their return to Australia, an ultrasound revealed the devastating truth.
'That's when our lives changed, you know? The doctor phoned me to say I had to come to the clinic immediately. Sofia had a tumour in her tummy, in her liver,' Alix told news.com.au.
The diagnosis was angiosarcoma, a rare and aggressive cancer usually seen in adults, not young children. The prognosis was grim.
Sofia's story is far from unique. In Australia, approximately 32,000 children live with life-limiting conditions.
Yet, according to the Australian Institute of Health and Welfare, in 2021 alone, an estimated 654 children died from these conditions, and less than half received specialist paediatric palliative care.
Palliative care is specialised medical support for people with life-limiting illnesses, focused on improving quality of life rather than prolonging it.
Yet despite its benefits, many families of critically ill children are never offered this care — a gap experts say must urgently be addressed.
In the wake of Sofia's diagnosis, what followed were months of surgeries, chemotherapy, radiotherapy, and unrelenting uncertainty. At one stage, doctors removed a vertebra from Sofia's spine and replaced it with titanium.
The young girl, once so lively and full of energy, woke from surgery unable to walk, plagued by burning sensations and neurological issues.
'When you talk about the treatment, that's what hurts the most,' Alix says, her voice faltering with grief as she recalls the needles, the fever, the feeding tube.
'That is the part that becomes difficult.'
For a while, Sofia returned to school. But the cancer came back, this time in her foot and hip. The doctors understood Sofia would not survive.
'They knew she would die but they didn't tell us: 'This is the path.' 'Communication was absent,' Alix explained.
Instead, a cycle of vague suggestions for further chemotherapy and radiotherapy continued, even after it was clear Sofia's cancer was terminal. Alix remembers the moment she and her husband were encouraged to consider yet more treatment.
'We couldn't understand. If she's going to die and the cancer is going to keep growing, why are you offering her chemo and radio,' she said.
The family had reached breaking point.
'We didn't want to be disrespectful, but we wanted to scream at the doctor and say: 'Are you stupid? Why do you want her to have that?' So, she's going to last six more months and she will die, vomiting, bald, not eating and with a tube. Horrible!'
In that moment, Alix did something many parents never feel empowered to do. She took a deep breath and asked for something radically different.
'I said, 'When the time comes, can you help her to die well? I don't want her to suffer.''
Only then, after Alix specifically requested it, was Sofia referred to specialist palliative care services.
This delay is heartbreakingly common, according to experts like Sara Fleming, an Adelaide-based nurse practitioner with nearly 25 years' experience in paediatric palliative care.
'The most heartbreaking thing that used to happen, and sometimes still does, is when referrals come late, and a family would sit there asking, 'Where have you been? Why didn't we meet you before?''
Sara recalls her early days in the sector when families with dying children were left isolated, afraid, and unsupported.
'There was a level of suffering that didn't need to be there, just because of a lack of knowledge and a lack of outreach from health professionals.'
In the wider community, families face social isolation too. Friends, neighbours and acquaintances often don't know how to cope, so they simply disappear.
'You represent the unthinkable,' Sara says. 'These diagnoses, these things that kill people's kids … it's generally just a s**tful roll of the dice. And so, you reflect, 'There by the grace of God, goes me.''
Alix experienced this first-hand. 'When a kid gets sick, everyone is so panicked, and people don't talk to you anymore because they don't know how to manage,' she explained.
Yet, as Alix and experts like Sara argue, early, honest conversations about prognosis, treatment options, and palliative care could dramatically change families' experiences.
Sara believes paediatric palliative care is fundamentally different from end-of-life care for adults.
Children often live with life-limiting conditions for years, while still navigating normal developmental challenges like puberty, friendships and schooling.
'We're stepping into working alongside a family where their child has been diagnosed with a life-limiting illness or disease,' she said,
'However, in the meantime, what matters is the living of that life. For children, it's also about what happens after they die.
'What memories or mark will they leave behind? For kids, it's important that we have these conversations about what's their legacy.'
Alix's daughter Sofia was a perfect example of this.
'She was always laughing, even since she was four months old. She was so much fun, and even when she grew up, she was always cheeky.'
Sofia loved to paint, read, and collect rocks. Her bedroom is still filled with soft toys, books, and her framed artwork.
'Rocks?' I ask Alix, surprised.
Alix nods, laughing softly through tears. 'She used to pick them up and bring them to the house. And I used to throw them away so much! She was a different [type of] person, and she would speak up her mind.'
In Sofia's final months, Alix kept her promise: no more needles, no more invasive treatments. Her pain was managed, and she was surrounded by loved ones.
The night before she died, Sofia's family gathered for a prayer.
Alix whispered gently to her: 'When you dream, just follow the light, because you're going to be happy again. You're going to run again.'
Sofia died at home on June 7, 2020.
For Alix, one of the most painful parts of the experience remains the absence of clear, compassionate conversations from medical professionals early in Sofia's diagnosis.
'Don't make people suffer because you don't want people to die. It's not your job to save everyone,' she said.
Her message echoes what advocates have been fighting for decades to achieve: a health system where families like hers aren't left to fend for themselves, and where palliative care is offered early, not as a last resort.
A national first for Australia, the Paediatric Palliative Care National Action Plan is aiming to shift that reality.
Released in 2023 by Palliative Care Australia (PCA) after years of research and consultation, the Plan marks a significant step forward for Australian families and health professionals. Now in its second stage, PCA is working on nationwide awareness and implementation.
'This is a really important step for paediatric palliative care in Australia,' Annette Vickery, Projects Manager at PCA, told news.com.au.
'Having a national plan and clear guidelines means families and clinicians will finally have more consistency and support. I hope it makes a real difference in everyday practice — helping teams feel more confident and better equipped to care for children, wherever they are.'
The Plan has also led to the development of Australia's first paediatric palliative care clinical guidelines – which will be made public by the end of this year – as well as the nation's first Paediatric End-of-Life Care Communication course for health professionals.
This whole suite of work was co-designed with bereaved parents.
'Talking and communicating a terminal diagnosis is difficult and especially so when it involves children and young people,' Annette explained.
'It was very important that we equip and empower our health professionals with the right skills and tools to communicate meaningfully across different stages of the care journey and across diverse cultures.'
But Annette is clear: there is still a long way to go.
'Too many children who could benefit from paediatric palliative care are not referred early enough,' she said.
'Systemic barriers like workforce shortages, lack of community-based services, lack of connections between specialists, and the stigma attached to the term 'palliative care' often delay or limit access.'
The Plan specifically acknowledges the inequities faced by families outside major cities, those from disadvantaged backgrounds, and children with non-cancer conditions — groups who often miss out on timely care altogether.
To tackle this, the Plan recommends workforce training, culturally safe care, and expanding outreach services, including for families in rural and remote areas.
Annette also believes it's about reframing how society understands palliative care. 'When palliative care is seen only as end-of-life care, families and health professionals often delay referrals, fearing it means giving up hope,' she explained.
'What's lost is the chance to make memories, and spend the last days, months or years doing what matters most with your loved ones.'
For Sara, it's time for the health workforce to face the uncomfortable truth.
'It's about the clinician saying, 'This is not a failure.' It's not a failure to acknowledge that maybe time might be short.'
Her hope, like Alix's, is for a cultural shift — one that finally brings children's palliative care out of the shadows.
'If we start teaching kids about death, since they are little, they will take it as natural from childhood into adulthood,' Alix added.
And, perhaps, families like hers will no longer have to navigate the unimaginable alone.
For anyone seeking further information and resources about paediatric palliative care, start here.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Health Check: Neuren says the US Rett syndrome market is a case of glass half full
Health Check: Neuren says the US Rett syndrome market is a case of glass half full

News.com.au

time26 minutes ago

  • News.com.au

Health Check: Neuren says the US Rett syndrome market is a case of glass half full

Neuren's US partner Acadia reports a 14% sales boost Look out for a slew of advanced clinical trial results in early 2026 IDT Australia shares plunge up to 39% after CEO departs 'with immediate effect' Despite firming US sales of its Rett syndrome treatment Daybue, Neuren Pharmaceuticals (ASX:NEU) says two-thirds of eligible patients are yet to try the drug. Neuren's US partner Acadia Pharmaceuticals overnight reported quarterly net sales of US$96.1 million, up 14% year on year. The Nasdaq-listed Acadia says a record number of patients received a shipment, growing for the third consecutive quarter. Acadia holds the global rights to Daybue and pays royalties to Neuren, which initially developed the drug. Affecting boys, Rett syndrome is a rare neurodevelopmental disorder resulting in slow development after the ages of six to 18 months. Acadia has guided to net sales of US$380-405 million, which at the current exchange rate will generate $62-67 million of royalties for Neuren in calendar 2025. Neuren earned $14.7 million in the June quarter, up 16% year on year. By their nature, royalties are pretty much pure profit. More patients – and they're more persistent Acadia says a record 987 patients received Daybue in the quarter, up from 954 in the March quarter. Despite concerns about side effects, 50% of patients persisted after 12 months' treatment. Neuren adds that 70% of active patients have now been on therapy for 12 months or longer. This was up from 65% previously. The company says two-thirds of the 5500 to 5800 diagnosed US patients are yet to try Daybue. The FDA approved the therapy in March 2023 and Acadia expects European assent in the March 2026 quarter. Neuren shares this morning spurted as much as 8%. They've more than doubled since their mid-April trough of $8.60. Investors spoil IDT's golden jubilee Veteran contract drug maker IDT Australia's (ASX:IDT) golden jubilee has been spoiled by a savage share rout, resulting from the news that CEO Paul McDonald would depart 'with immediate effect'. The company also issued a lacklustre trading update, flagging a boost in revenue for the year to June 30, 2025, but a widening loss. A former Pfizer exec, McDonald had been in the job for almost three years. Chairman Mark Simari becomes executive chair while the company searches for a new CEO. IDT says its full-year revenue should come in at $19.9 million, a 40% increase. The company cites an increase in disbursement revenue. This derived from raw material costs and equipment charged to customers at a 'modest' margin. IDT says mainly applying to new contracts, disbursements are a 'positive lead indicator'. IDT also expects a net loss of $7.5 million, compared with a $5.4 million deficit last year. This reflects $1.2 million of bad debts from two customers defaulting on payments. Founded in 1975, IDT has had a convoluted history, including missing out on a government funded Covid vaccine plant at the last minute. These days IDT pursues gene technology, antibody drug conjugates, medical marijuana and psychedelic treatments for mental disorders. The company is in the third year of its five-year strategy, spurred by a board 'refresh' in September 2022. IDT's $30 million worth is backed by the value of the company's Boronia premises in eastern Melbourne. This hard-to-replicate is in the books at a conservative $21 million. We're on track, say drug developers Investors can look forward to a slew of company-making trial results in 2026, according to presenters at this year's Bioshares summit in Hobart. Alzheimer's disease drug developer Actinogen Medical (ASX:ACW) says it's on track to report interim results from its advanced phase IIb/III trial, by January next year. The company is enrolling 220 patients for its Xanamia trial for mild to moderate sufferers, across 15 Australian and 20 US sites. Actinogen's candidate Xanamem targets excess levels of cortisol in the brain – a novel mechanism of action. The company expects to unveil data from the first 100 patients, after 24 weeks' treatment. Final results are expected in late 2026. Stem cell developer Cynata Therapeutics (ASX:CYP) expects to release results of its phase III osteoarthritis (OA) trial between February and April next year. Cynata's mesenchymal stromal cells modulate the immune system and enable tissue repair. The OA program is the most advanced of Cynata's four trials that also cover graft-versus-host disease, diabetic foot ulcers and kidney transplants. Vitiligo is a circa US$500 million market, says Clinuvel The developer of an approved treatment for a rare sun intolerance disorder abbreviated as EPP, Clinuvel Pharmaceuticals (ASX:CUV) is advancing its proposed treatment for the more common vitiligo. The company has fully enrolled its 210 patient phase III trial, with a readout due in the June half. Affecting about 1% of the population, vitiligo is skin discolouration that results from the destruction of pigment-producing cells called melanocytes. The late Michael Jackson was a celebrity sufferer. If the drug gets US Food and Drug Administration (FDA) approval, the company estimates US$490-570 million of revenue in years one and two. Put in context, Clinuvel reported revenue of $35.6 million in the 2024 December half, up 10%. These sales derived from the company's EPP treatment, Scenesse. Doing the numbers on Imricor Broker Canaccord reckons Imricor Medical Systems (ASX:IMR) could be worth more than twice its current valuation – but faces constrained hospital budgets for the time being. In a 60-page appraisal of the cardiac ablation catheter developer, the firm estimates 120 US hospitals could be using the device within five years. Assuming 35% penetration of the ablation procedures, this equates to a $2.50 per share valuation compared with around $1.40 now. 'The big question ... is how quickly can these installs happen,' the firm says. Uniquely, Imricor's catheters are guided in real-time with magnetic resonance imaging – MRI – rather than via x-ray. The procedure is called interventional cardiac magnetic resonance cardiac ablation (ICMR CA). The company initially is focused on the US$12b arrhythmia market. Canaccord believes Imricor is still 12-18 months away from a 'material revenue ramp'. But after that it's off to the races. Imricor has an initial US target market as 120 large academic hospitals, 20 of them high volume. The firm estimates that facilities will install 190 ICMR US labs globally five years post launch. Of these, 100 will be in the US with total revenue of US$250 million. Imricor currently is undertaking a trial aimed at FDA approval for atrial flutter procedures, with a decision by the end of 2026.

Indonesian protesters call for Australia to stop sending plastic waste as microplastic found in foetuses
Indonesian protesters call for Australia to stop sending plastic waste as microplastic found in foetuses

News.com.au

timean hour ago

  • News.com.au

Indonesian protesters call for Australia to stop sending plastic waste as microplastic found in foetuses

Furious scenes have erupted outside an Australian embassy overseas, with protesters claiming their babies are being 'poisoned'. Environmental activists in the Indonesian city of Surabaya have demanded Australia stops sending plastic waste to Indonesia, arguing the contaminated waste has developed micro plastics in foetuses. Protesters dragged two large dolls in front of the Australian Consulate-General to depict a scene of babies engulfed by contaminated plastic waste, and a mannequin of a pregnant mother. They arrived also with masks, signs and a megaphone relaying their message. 'Australia's plastic waste is poisoning out babies,' one sign read. 'Your plastic lifestyle destroys babies' future,' another read. The news comes as Ecological Observation and Wetland Conservation (ECOTON) recently revealed Australia was the largest exporter of plastic waste to Indonesia between 2020 and 2024, sending more than 2.7 billion kilograms, according to the UN Comtrade Database. It also found more than 60 per cent of paper waste sent from Australia to Indonesia was contaminated either by flexible plastics scrap, multilayer plastic or soiled plastic packaging. Such materials cannot be recycled and end up building up at illegal dump sites. Even more concerning, in late 2014 ECOTON tested more than 80 baby care products and found nearly 60 per cent of them contained microbeads, which are tiny plastics that enter the body through the skin. 'We found that microplastics were already present in the foetus,' one protester said. 'Then our findings show they were in the placenta, meaning these small plastic particles were already able to penetrate the placenta and also the amniotic fluid. 'Now, this can be concerning for the future of this nation's life.' The move aims to put pressure on the Australian government to reconsider how it disposes of plastic waste and the impact on the Indonesian people. It's another push drawing attention to the matter that has become a big talking point Indonesia, with protests becoming almost routine. Protesters organised a similar event last year in July when the 'Your Trash Drowns Us' protest was held in the same spot outside the embassy, demanding the Australian government to stop sending plastic waste that was impacting the environment in East Java. 'I've heard of the concept of Laudato Si' from Pope Francis. Are we going there? Hopefully,' Indonesian environmentalist Prigi Arisandi said. Laudato Si', the then-pope's encyclical from 2015, stressed the international obligation to take care of the environment, with a call for ecological conversion.

Brandy production returns to Coonawarra as winery revives distilling heritage
Brandy production returns to Coonawarra as winery revives distilling heritage

ABC News

timean hour ago

  • ABC News

Brandy production returns to Coonawarra as winery revives distilling heritage

For the first time in decades, brandy is returning to the Coonawarra. The region was once a major producer of the wine-based liquor, before it dropped out of fashion. The idea to bring back brandy to the Coonawarra came from the director of Majella Wines, Brian "Prof" Lynn. After contemplating launching a spirit, he thought brandy would be the most natural progression from wine. It has so far been a straightforward addition for the business, requiring only a distillation still in addition to their existing wine, rainwater and wooden ageing barrels. Mr Lynn has found the distilling process to be quick, only taking about six hours. But the ageing process is slow, with all brandy legally required to be aged for two years in a wooden cask. Despite the strong historic origins of brandy in the region, Majella's release is the first to include the region on the labelling. In the early 1900s, tastes were changing and demand for dry reds dwindled. The brandy produced with the surplus grapes would eventually become generically branded brandy. But as other wine varieties grew in popularity, Coonawarra's brandy production declined and eventually stopped in the late 20th century. Much of the knowledge about Coonawarra brandy has been lost through the decades, but there are some in the region still with connections to the liquor. Coonawarra resident Diana Clayfield's father, Arthur Hoffmann, was a viticulturalist, wine and brandy maker in the region. "He enjoyed doing it [making brandy]," she said. Ms Clayfield remembers the generation before her enjoying a brandy, and sometimes even using it for medicinal purposes. "If you had a flu, they warmed brandy and wine up together and had it as a medicine," she said. It was this connection with medicine that helped brandy to become so popular, with production peaking in the 1960s. Luke McCarthy has extensively researched and written about Australian spirits and brandy. He said hospital brandy emerged around the turn of the 20th century, with major brands producing it into the 1940s. The term fell out of vogue around the same time brandy production declined. Another blow was the federal excise on brandy, facing a large increase in the 1970s to be closer to other spirits. "It's a combination of economic forces, government intervention and then shifting consumer trends, which have seen brandy really ride this sort of roller coaster ride over the last 100 years," Mr McCarthy said. Australian Distillers Association president Holly Klintworth said, although the market for other spirits like gin had become crowded, there was an opportunity ahead for brandy. "There's definitely a place in Australia for brandy and I hope that it's only a matter of time before more and more people start to rediscover just how amazing brandy can be," she said. And it could be a money spinner for wineries — Ms Klintworth's distillery turns "about $16,000 worth of wine into the equivalent of $1.5 million worth of brandy". "It makes a lot of sense. We've got so many wine regions," she said. Mr Lynn agrees that conditions are right for a comeback. He was already ageing a fresh batch of brandy to release in future years. "In the old days, brandy was huge; everyone drank brandy," he said.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store